Sequana Medical NV

Chart & Performance

D1W1MN

P/E

—

P/S

453.50

EPS

—

Div Yield, %

—

Shrs. gr., 5y

24.38%

Rev. gr., 5y

-35.78%

Revenues

106k

-85.12%

Net income

-45m

L+37.13%

CFO

-20m

L-29.74%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.

URL

https://www.sequanamedical.com/

IPO date

Feb 11, 2019

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title EUR in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title EUR in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT